1804910-11-9
1804910-11-9
Chemical Structure
Valziflocept
Synonym(s): BAX1810; TAK-752; SM101
- CAS No.: 1804910-11-9
- Formula:N/A
- Molecular Weight:(19.693 kDa)
IUPAC Name: methyl 2-bromo-3,5,6-trifluorobenzoate
SMILES: [Valziflocept]
Biological Activity: Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Valziflocept | 99.00% | Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Magnusson SE, et al. Amelioration of collagen-induced arthritis by human recombinant soluble FcgammaRIIb. Clin Immunol. 2008;127(2):225-233. [Content Brief]
- [2]. Werwitzke S, et al. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32). Ann Rheum Dis. 2008 Feb;67(2):154-61. [Content Brief]
- [3]. Zuercher AW, et al. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10):102366. [Content Brief]
